In addition, miR-130a acts as a tumor suppressor in prostate cancer and triple-negative breast cancer, inhibiting androgen receptor (AR) and mitogen-activated protein kinase (MAPK) pathways and targeting foS-like antigen 1 (FOSL1) (Boll et al., 2013; Chen et al., 2018). This evidence concerns the gene AR and prostate cancer.